Recent Finacing
Recent Raise
Thelper develops an antibody-drug conjugate targeting US28, a virus-derived marker in aggressive solid tumors, and is conducting pre-IND in vivo validation, pharmacokinetic, and toxicology studies.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors
